The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.

ABSTRACT:

Background

VEGF may play a role in the pathogenesis of cancer disease, for example in cell growth, proliferation and angiogenesis. In this study, we investigated plasma levels of this cytokine in comparison to plasma levels of a new biomarker - HE4 and the established tumor marker CA125 in ovarian cancer patients (100) as compared to control groups: patients with a benign ovarian tumor (80) and healthy subjects (50).

Methods

Plasma levels of VEGF were determined by ELISA, HE4 and CA125 by CMIA method.

Results

The results showed that levels of VEGF, CA125 and HE4 were significantly higher in ovarian cancer (OC) patients as compared to the both control groups. VEGF has demonstrated as high as comparative markers values of the diagnostic sensitivity (SE), specificity (SP

SUBMITTER: Lawicki S 

PROVIDER: S-EPMC3706238 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature